Commons Sense

House of Commons · Written Ministerial Statement

Covid-19 Update

19 January 2022 · Department of Health and Social Care

Proposed by Sajid Javid Con Bromsgrove

NHS

Summarised by AI from the official record, so it can contain mistakes.

View on Parliament.uk

At a glance

Key points

  • The Government has purchased 2.5 million additional patient courses of PF-07321332+ritonavir.
  • PF-07321332+ritonavir has been granted conditional marketing authorisation.
  • Antivirals are considered crucial for resilience against COVID-19.

Issue summary

The statement addresses the procurement and contingent liability associated with the antiviral drug PF-07321332+ritonavir (Paxlovid) for treating UK COVID-19 patients.

Action requested

The Government has purchased 2.5 million additional patient courses of PF-07321332+ritonavir and granted it conditional marketing authorisation to ensure access to supply across the UK, while also noting that antivirals provide an important layer of resilience in the fight against COVID-19.

Key facts

  • The Government purchased 250,000 patient courses of PF-07321332+ritonavir on 20 October 2021.
  • An additional 4.25 million antiviral treatments were procured on 22 December, including 2.5 million patient courses of PF-07321332+ritonavir.
  • On 31 December 2021, PF-07321332+ritonavir was granted a conditional marketing authorisation by the MHRA and a temporary Regulation 174 authorisation for Northern Ireland.
▸ Assessment & feedback
Summary accuracy